Prognostic value of monitoring a candidate immunophenotypic leukemic stem/progenitor cell population in patients allografted for acute myeloid leukemia

[1]  D. Grimwade,et al.  Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"? , 2014, Blood.

[2]  W. Hiddemann,et al.  Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  C. Craddock.  Pharmacological methods to reduce disease recurrence. , 2013, Hematology. American Society of Hematology. Education Program.

[4]  I. Weissman,et al.  Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia , 2013, Leukemia.

[5]  E. Estey.  How to manage high-risk acute myeloid leukemia , 2012, Leukemia.

[6]  B. Seliger,et al.  Clonal Evolution Including Partial Loss of Human Leukocyte Antigen Genes Favoring Extramedullary Acute Myeloid Leukemia Relapse After Matched Related Allogeneic Hematopoietic Stem Cell Transplantation , 2012, Transplantation.

[7]  N. Kröger,et al.  Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. , 2012, Blood.

[8]  P. Vyas,et al.  Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. , 2011, Cancer cell.

[9]  M. Carroll,et al.  Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice. , 2011, The Journal of clinical investigation.

[10]  J. Gribben,et al.  Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. , 2010, Blood.

[11]  F. Appelbaum.  Optimising the conditioning regimen for acute myeloid leukaemia. , 2009, Best practice & research. Clinical haematology.

[12]  เอกรัฐ รัฐฤทธิ์ธำรง.  Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation , 2009 .

[13]  J. Dick,et al.  Stem cell concepts renew cancer research. , 2008, Blood.

[14]  G. Schuurhuis,et al.  Aberrant marker expression patterns on the CD34+CD38− stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission , 2007, Leukemia.

[15]  D. Olive,et al.  Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. , 2000, Cancer research.